Physicians' Academy for Cardiovascular Education

Targeting triglyceride-rich remnant lipoproteins

10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD - Montreal, QC, Canada

Video navigation menu

  • Current and emerging therapies targeting triglyceride-rich lipoproteins 1:45
  • Mechanisms of action of ApoC3 and ANGPTL3 inhibitors 3:14
  • Clinical trials targeting apoC3 for hypertriglyceridemia 4:12
  • Clinical trials targeting ANGPTL3 for hypertriglyceridemia 6:59
  • Effects and mechanisms of action of ApoC3 and ANGPTL3 inhibitors on triglyceride-rich lipoproteins 11:36
  • Conclusion 13:03

Angiopoietin-like 3 (ANGPTL3) blockade

  • A. involves LPL-dependent and LPL-independent mechanisms
  • B. involves LPL-dependent and LDL receptor-independent mechanisms
  • C. lowers TG levels, but not non-HDL-c levels
  • D. results in larger reduction of TG-rich remnants than ApoCIII inhibition
Show the correct answer

Transcript

Show transcript

Educational information

This lecture by Daniel Gaudet is part of a series titled "Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities".

This program has been designed to educate physicians and other healthcare professionals with an interest in CV risk on lipid-associated residual risk beyond LDL-c and provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to use findings from studies on triglyceride-rich lipoproteins in the treatment of patients in clinical practice.

Faculty

Prof. Daniel Gaudet, MD, PhD - Clinical Lipidology and Rare Lipid Disorders Unit, CMGC Department of Medicine, Université de Montréal, QC, Canada

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from Pfizer Inc.

Click here for the meeting report View slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: